Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.

Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath.Wall Street loves a dominant player, and Eli Lilly (LLY 2.73%) looks unstoppable with its obesity blockbusters printing money faster than the Fed. But here's what the bulls aren't telling you: The company's next-generation oral weight-loss pill just delivered a reality check, and a scrappy competitor is positioning itself to steal the most lucrative slice of the $100 billion obesity treatment market.At today's premium v ...